The investment will establish drug product manufacturing capacity for clinical trial and commercial supply in China and offer customers combined drug substance and drug product manufacturing services
Goal of providing 12-month internship opportunities for qualified students
The agreement is to develop, manufacture and commercialise biosimilars for the global market.
CRISIL Ratings has revised its outlook on the long term ratings of Krishna Institute Of Medical Sciences Limited (KIMS) to 'Positive' from 'Stable' while reaffirming the ratings at 'CRISIL AA-/CRISIL A1+'
The co-investment of CHF 4 million will result in capacity expansion and support the market introduction of the customer's lead compound
First and only therapy approved by the FDA for the treatment of pruritus associated with chronic kidney disease (CKD-aP) in adults undergoing hemodialysis
Trillium’s portfolio includes biologics that are designed to enhance the ability of patients’ innate immune system to detect and destroy cancer cells
The foundation has been working closely with the Kidwai Memorial Institute of Oncology on several projects since 2001
The module offers the first preclinical laboratory information system of its kind that is fully integrated into the digital pathology workflow and provides efficient pathological studies of whole slides
It is the first branded generic alternative to Fostair 100/6 pMDI
Subscribe To Our Newsletter & Stay Updated
